Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans

Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans

Dermatofibrosarcoma protuberans (DFSP) is a rare sarcoma, characterized by a <i>COL1A1-PDGFB</i> fusion. Imatinib, a multi-target tyrosine kinase inhibitor, is a standard treatment of DFSP. However, resistance emerges in 10–50% of cases. There is an urgent need for predictive biomarkers...

Full description

Saved in:
Bibliographic Details
Main Authors: Rei Noguchi, Takuya Ono, Kazuki Sasaki, Mari Masuda, Akira Kawai, Yuki Yoshimatsu, Tadashi Kondo
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Cells
Subjects:
dermatofibrosarcoma protuberans
sarcoma
patient-derived cell line
kinase activity
imatinib
drug screening
Online Access:https://www.mdpi.com/2073-4409/14/12/884
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2073-4409/14/12/884

Similar Items